Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Contineum Therapeutics (CTNM) EBITDA Margin (2023)

Contineum Therapeutics (CTNM) has 1 years of EBITDA Margin data on record, last reported at 83.02% in Q2 2023.

  • For Q2 2023, EBITDA Margin changed N/A year-over-year to 83.02%; the TTM value through Mar 2024 reached 38.16%, changed N/A, while the annual FY2023 figure was 45.81%, N/A changed from the prior year.
  • EBITDA Margin reached 83.02% in Q2 2023 per CTNM's latest filing, down from 5170.65% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 5170.65% in Q1 2023 and bottomed at 83.02% in Q2 2023.